Compare Mesoblast Limited (MESO) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs MPLX LP — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while MPLX LP trades at $56.69 (market cap $57.97B). The key difference: MPLX LP is far larger — about 26.7× Mesoblast Limited's market cap, and MPLX LP pays a 7.54% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | MPLX | |
|---|---|---|
Market Cap | $2.17B | $57.97B |
Sector | Technology | Technology |
52-Week High | $20.96 | $59.17 |
52-Week Low | $12.88 | $47.80 |
Enterprise Value | $2.17B | $82.60B |
Dividend Yield | — | 7.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
MPLX trades at $57.13, up 0.12% today, with a bullish technical signal from moving averages and a consensus analyst price target of $60.00. The company reported strong profitability with a 41.24% net income margin in 2025 and has beaten earnings estimates in two of the last three quarters. Recent news highlights its resilient midstream model and attractive dividend yield.
The outlook for MPLX is positive, supported by stable cash flows, a high dividend yield, and analyst optimism. Key risks include exposure to energy market volatility and a recent earnings miss. The stock offers value with a P/E of 12.35 and strong institutional buy ratings, but investors should monitor execution on growth projects and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
